Administration of carnosine in the treatment of acute spinal cord injury

Rosanna Di Paola, Daniela Impellizzeri, Angela Trovato Salinaro, Emanuela Mazzon, Francesco Bellia, Monia Cavallaro, Carolin Cornelius, Graziella Vecchio, Vittorio Calabrese, Enrico Rizzarelli, Salvatore Cuzzocrea

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

l-Carnosine is an endogenously synthesized dipeptide composed of beta-alanine and l-histidine. It acts as a free radical scavenger and possesses antioxidant properties. l-Carnosine reduces proinflammatory and profibrotic cytokines such as transforming growth factor-beta (TGF-beta), interleukin (IL)-1, and tumor necrosis factor (TNF)-alpha in different experimental settings. In the present study, we investigated the efficacy of l and d-carnosine on the animal model of spinal cord injury (SCI). The spinal cord was exposed via a four-level T5-T8 laminectomy and SCI was produced by extradural compression of the spinal cord at level T6-T7 using an aneurysm clip with a closing force of 24 g. Treatment with d-carnosine (150 mg/kg administered i.p., 1 h and 6 h, after SCI), but not l-carnosine significantly decreased (a) the degree of spinal cord inflammation and tissue injury (histological score), (b) neutrophil infiltration (myeloperoxidase activity), (c) nitrotyrosine formation, inducible NO synthase (iNOS) and Hsp70 expression, (d) proinflammatory cytokines, and (e) apoptosis (TUNEL staining, Fas ligand, Bax, and Bcl-2 expression). Furthermore, d-carnosine (150 mg/kg administered i.p., 1 h and 6 h, after SCI) significantly ameliorated the loss of limb function (evaluated by motor recovery score). Taken together, our results demonstrate the strong difference between l-carnosine and d-carnosine. The result strongly suggests that d-carnosine treatment reduces the development of inflammation and tissue injury associated with spinal cord trauma.

Original languageEnglish
Pages (from-to)1478-1489
Number of pages12
JournalBiochemical Pharmacology
Volume82
Issue number10
DOIs
Publication statusPublished - Nov 15 2011

Fingerprint

Carnosine
Spinal Cord Injuries
Tissue
Cytokines
Myelitis
beta-Alanine
Free Radical Scavengers
Spinal Cord Compression
Fas Ligand Protein
Laminectomy
Neutrophil Infiltration
Dipeptides
In Situ Nick-End Labeling
Wounds and Injuries
Interleukin-1
Infiltration
Histidine
Surgical Instruments
Nitric Oxide Synthase
Transforming Growth Factor beta

Keywords

  • Apoptosis
  • Carnosine
  • Inflammation
  • Spinal cord injury

ASJC Scopus subject areas

  • Pharmacology
  • Biochemistry

Cite this

Di Paola, R., Impellizzeri, D., Salinaro, A. T., Mazzon, E., Bellia, F., Cavallaro, M., ... Cuzzocrea, S. (2011). Administration of carnosine in the treatment of acute spinal cord injury. Biochemical Pharmacology, 82(10), 1478-1489. https://doi.org/10.1016/j.bcp.2011.07.074

Administration of carnosine in the treatment of acute spinal cord injury. / Di Paola, Rosanna; Impellizzeri, Daniela; Salinaro, Angela Trovato; Mazzon, Emanuela; Bellia, Francesco; Cavallaro, Monia; Cornelius, Carolin; Vecchio, Graziella; Calabrese, Vittorio; Rizzarelli, Enrico; Cuzzocrea, Salvatore.

In: Biochemical Pharmacology, Vol. 82, No. 10, 15.11.2011, p. 1478-1489.

Research output: Contribution to journalArticle

Di Paola, R, Impellizzeri, D, Salinaro, AT, Mazzon, E, Bellia, F, Cavallaro, M, Cornelius, C, Vecchio, G, Calabrese, V, Rizzarelli, E & Cuzzocrea, S 2011, 'Administration of carnosine in the treatment of acute spinal cord injury', Biochemical Pharmacology, vol. 82, no. 10, pp. 1478-1489. https://doi.org/10.1016/j.bcp.2011.07.074
Di Paola R, Impellizzeri D, Salinaro AT, Mazzon E, Bellia F, Cavallaro M et al. Administration of carnosine in the treatment of acute spinal cord injury. Biochemical Pharmacology. 2011 Nov 15;82(10):1478-1489. https://doi.org/10.1016/j.bcp.2011.07.074
Di Paola, Rosanna ; Impellizzeri, Daniela ; Salinaro, Angela Trovato ; Mazzon, Emanuela ; Bellia, Francesco ; Cavallaro, Monia ; Cornelius, Carolin ; Vecchio, Graziella ; Calabrese, Vittorio ; Rizzarelli, Enrico ; Cuzzocrea, Salvatore. / Administration of carnosine in the treatment of acute spinal cord injury. In: Biochemical Pharmacology. 2011 ; Vol. 82, No. 10. pp. 1478-1489.
@article{b4ae604cca674df9ad689cb2a1958b93,
title = "Administration of carnosine in the treatment of acute spinal cord injury",
abstract = "l-Carnosine is an endogenously synthesized dipeptide composed of beta-alanine and l-histidine. It acts as a free radical scavenger and possesses antioxidant properties. l-Carnosine reduces proinflammatory and profibrotic cytokines such as transforming growth factor-beta (TGF-beta), interleukin (IL)-1, and tumor necrosis factor (TNF)-alpha in different experimental settings. In the present study, we investigated the efficacy of l and d-carnosine on the animal model of spinal cord injury (SCI). The spinal cord was exposed via a four-level T5-T8 laminectomy and SCI was produced by extradural compression of the spinal cord at level T6-T7 using an aneurysm clip with a closing force of 24 g. Treatment with d-carnosine (150 mg/kg administered i.p., 1 h and 6 h, after SCI), but not l-carnosine significantly decreased (a) the degree of spinal cord inflammation and tissue injury (histological score), (b) neutrophil infiltration (myeloperoxidase activity), (c) nitrotyrosine formation, inducible NO synthase (iNOS) and Hsp70 expression, (d) proinflammatory cytokines, and (e) apoptosis (TUNEL staining, Fas ligand, Bax, and Bcl-2 expression). Furthermore, d-carnosine (150 mg/kg administered i.p., 1 h and 6 h, after SCI) significantly ameliorated the loss of limb function (evaluated by motor recovery score). Taken together, our results demonstrate the strong difference between l-carnosine and d-carnosine. The result strongly suggests that d-carnosine treatment reduces the development of inflammation and tissue injury associated with spinal cord trauma.",
keywords = "Apoptosis, Carnosine, Inflammation, Spinal cord injury",
author = "{Di Paola}, Rosanna and Daniela Impellizzeri and Salinaro, {Angela Trovato} and Emanuela Mazzon and Francesco Bellia and Monia Cavallaro and Carolin Cornelius and Graziella Vecchio and Vittorio Calabrese and Enrico Rizzarelli and Salvatore Cuzzocrea",
year = "2011",
month = "11",
day = "15",
doi = "10.1016/j.bcp.2011.07.074",
language = "English",
volume = "82",
pages = "1478--1489",
journal = "Biochemical Pharmacology",
issn = "0006-2952",
publisher = "Elsevier Inc.",
number = "10",

}

TY - JOUR

T1 - Administration of carnosine in the treatment of acute spinal cord injury

AU - Di Paola, Rosanna

AU - Impellizzeri, Daniela

AU - Salinaro, Angela Trovato

AU - Mazzon, Emanuela

AU - Bellia, Francesco

AU - Cavallaro, Monia

AU - Cornelius, Carolin

AU - Vecchio, Graziella

AU - Calabrese, Vittorio

AU - Rizzarelli, Enrico

AU - Cuzzocrea, Salvatore

PY - 2011/11/15

Y1 - 2011/11/15

N2 - l-Carnosine is an endogenously synthesized dipeptide composed of beta-alanine and l-histidine. It acts as a free radical scavenger and possesses antioxidant properties. l-Carnosine reduces proinflammatory and profibrotic cytokines such as transforming growth factor-beta (TGF-beta), interleukin (IL)-1, and tumor necrosis factor (TNF)-alpha in different experimental settings. In the present study, we investigated the efficacy of l and d-carnosine on the animal model of spinal cord injury (SCI). The spinal cord was exposed via a four-level T5-T8 laminectomy and SCI was produced by extradural compression of the spinal cord at level T6-T7 using an aneurysm clip with a closing force of 24 g. Treatment with d-carnosine (150 mg/kg administered i.p., 1 h and 6 h, after SCI), but not l-carnosine significantly decreased (a) the degree of spinal cord inflammation and tissue injury (histological score), (b) neutrophil infiltration (myeloperoxidase activity), (c) nitrotyrosine formation, inducible NO synthase (iNOS) and Hsp70 expression, (d) proinflammatory cytokines, and (e) apoptosis (TUNEL staining, Fas ligand, Bax, and Bcl-2 expression). Furthermore, d-carnosine (150 mg/kg administered i.p., 1 h and 6 h, after SCI) significantly ameliorated the loss of limb function (evaluated by motor recovery score). Taken together, our results demonstrate the strong difference between l-carnosine and d-carnosine. The result strongly suggests that d-carnosine treatment reduces the development of inflammation and tissue injury associated with spinal cord trauma.

AB - l-Carnosine is an endogenously synthesized dipeptide composed of beta-alanine and l-histidine. It acts as a free radical scavenger and possesses antioxidant properties. l-Carnosine reduces proinflammatory and profibrotic cytokines such as transforming growth factor-beta (TGF-beta), interleukin (IL)-1, and tumor necrosis factor (TNF)-alpha in different experimental settings. In the present study, we investigated the efficacy of l and d-carnosine on the animal model of spinal cord injury (SCI). The spinal cord was exposed via a four-level T5-T8 laminectomy and SCI was produced by extradural compression of the spinal cord at level T6-T7 using an aneurysm clip with a closing force of 24 g. Treatment with d-carnosine (150 mg/kg administered i.p., 1 h and 6 h, after SCI), but not l-carnosine significantly decreased (a) the degree of spinal cord inflammation and tissue injury (histological score), (b) neutrophil infiltration (myeloperoxidase activity), (c) nitrotyrosine formation, inducible NO synthase (iNOS) and Hsp70 expression, (d) proinflammatory cytokines, and (e) apoptosis (TUNEL staining, Fas ligand, Bax, and Bcl-2 expression). Furthermore, d-carnosine (150 mg/kg administered i.p., 1 h and 6 h, after SCI) significantly ameliorated the loss of limb function (evaluated by motor recovery score). Taken together, our results demonstrate the strong difference between l-carnosine and d-carnosine. The result strongly suggests that d-carnosine treatment reduces the development of inflammation and tissue injury associated with spinal cord trauma.

KW - Apoptosis

KW - Carnosine

KW - Inflammation

KW - Spinal cord injury

UR - http://www.scopus.com/inward/record.url?scp=80054715568&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80054715568&partnerID=8YFLogxK

U2 - 10.1016/j.bcp.2011.07.074

DO - 10.1016/j.bcp.2011.07.074

M3 - Article

C2 - 21787762

AN - SCOPUS:80054715568

VL - 82

SP - 1478

EP - 1489

JO - Biochemical Pharmacology

JF - Biochemical Pharmacology

SN - 0006-2952

IS - 10

ER -